Inflammatory Cytokine Levels in Pulmonary Embolism Severity: A Retrospective Study

Xiaoming Li
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Yukun Li
Dezhou people's hospital

Wenjing Ye
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Xi Chen
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Xuejun Guo
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Wen Gu (✉ guwen@xinhuamed.com.cn)
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Research Article

Keywords: cytokines, pulmonary embolism, severity, comorbidities

Posted Date: December 29th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1197499/v1

License: 😊 This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Inflammatory cytokines are involved in the development of venous thromboembolism (VTE) and may influence the mortality. But the association between their levels and severity of pulmonary embolism (PE) is unclear. This study aimed to investigate the association of inflammatory cytokines and PE severity.

Methods: We retrospectively analyzed patients who were admitted to Xinhua Hospital with a confirmed diagnosis of PE between Jan 2019 and Apr 2021. Inflammatory cytokines were compared among different severities of PE groups. Spearman rank-order correlation analysis and multivariate Logistic regression analysis were used to analyze the relationship between cytokine level and PE severity. In addition, we estimated the association between comorbidities and PE severity by using multivariate Logistic regression analysis.

Results: A negative correlation between IL-8 level and PE severity was found (r=-0.466, P=0.018). Comorbidities of coronary heart disease [3.76 (1.99-7.10) (P=0.000)], deep venous thrombosis [2.40 (1.15-5.01) (P=0.019)], respiratory failure [2.92 (1.33-6.4) (P=0.007)] were correlated with the severity of PE.

Conclusions: IL-8 level is negative correlated with PE severity. Patients with comorbidities regarding coronary heart disease, deep venous thrombosis, and respiratory failure may have higher risk to suffer a more severe PE.

Introduction

Venous thromboembolism (VTE), clinically presenting as deep vein thrombosis (DVT) or PE, is a common disorder with an estimated incidence of one to three per 1,000 population annually [1]. A rising tendency in VTE incidence rates has been revealed in epidemiological studies [2]. As reported, the incidence of VTE currently is almost 10-30 times higher than that in 20 years ago in China. Pulmonary embolism (PE) as the most frequent acute syndrome in respirology department is a potentially life-threatening disease. Accurate and prompt diagnosis is essential for reducing mortality. Once PE is diagnosed, risk stratification should be performed immediately. PE severity can be classified to low risk, intermediate risk (include intermediate-low risk and intermediate-high risk), and high risk. Treatments and prognosis are different among patients with different severities [3].

Increasing evidence revealed that cytokines are involved in the development of VTE and may influence the mortality [4]. These new insights into the role of cytokines in VTE have aroused Clinicians’ attention to anti-inflammatory therapy [5]. A recent review summarized the interplay between cytokines and venous thrombosis. Cytokines including IFNγ, IL-6, IL-17A, IL-9, IL-1β and TGF-β perform pro-thrombotic activity, while other cytokines such as IL-10, TNF-α and IL-8 appear to promote thrombus resolution in late phase of venous thromboembolism [6]. Anomalous cytokines levels and high PE frequency were found in patients with cancer, pneumonia, tuberculous pleural effusion, and other disease [7–9]. Abnormal cytokine levels caused by primary disease may involve in the development of PE. But the relationship
between cytokines and PE severity is unclear. Whether comorbidities would influence PE severity through cytokines is worth studying.

In the present study, we evaluated the relationship between cytokines and PE severity. In addition, we investigated the association of comorbidities and the severity of PE in patients.

**Methods**

**Study design and participants**

A retrospective study was conducted to investigate the association between cytokines as well as complications and PE severity. All the patients with confirmed diagnosis of PE in Xinhua hospital affiliated to Shanghai Jiao Tong University School of Medicine between Jan, 2019 and Apr, 2021 were reviewed. Interleukin (IL)-8, IL-6, IL-2R, tumor necrosis factor (TNF-α) and C-reactive protein (CRP), white blood cell (WBC) counts, erythrocyte sedimentation rate (ESR) as well as the rate of comorbidities were compared between different PE severity groups. The association between cytokines, inflammatory makers, comorbidities, and PE severity was analyzed.

This retrospective study only collected the clinical data of patients, did not interfere with the treatment plan of patients, and did not pose any risk to patients' physiology. Due to the retrospective nature of the study, informed consent was waived. All protocols were approved by the Ethics Committee of Xin Hua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine. (NO. XHEC-D-2021-170).

**Data Collection**

In our hospital, PE severity was stratified as soon as possible according to clinical appearance, systolic blood pressure, imaging for right ventricular dysfunction (CTA or echocardiography) and/or biomarkers (troponin, NT-pro-BNP) as described before [10]. According to the medical record, clinical data includes demographic information (age, gender, previous medical history, comorbidities), PE severity, laboratory tests (CRP, WBC counts, ESR, D-dimer, IL-6, IL-8, TNF-α, and IL-2 receptor) was collected.

**Statistical analysis**

SPSS version 22.0 (IBM Corporation, New York) was used for the statistical analysis. Data were presented as median with interquartile range. Categorical data were presented as frequencies or percentages. Comparison of median among groups was performed by using Kruskal-Wallis test. Comparison of rates among groups was performed by Chi-square test. The association between cytokines and the severities of PE was analyzed by using Spearman rank-order correlation analysis. The association between commodities and the severities of PE was analyzed by using ordinal multinomial Logistic regression analysis. Statistical significance was set at P < 0.05.
Results

The demographics and clinical characteristics of patients.

There were 256 patients in all. 51 patients who without complete clinical information were excluded. 205 patients were enrolled in this study, among whom 95 patients were low risk, 56 patients were intermediate-low risk, 30 patients were intermediate-high risk, 24 patients were high risk. The median age was 68 (interquartile range, (IQR):23-92) years old. The number of male and female patients were 87(42.4%) and 118 (57.6%) respectively. pleural effusion, pulmonary infection, coronary heart disease, hypertension, deep venous thrombosis, cardiac arrhythmia, carcinoma, respiratory failure, renal dysfunction, diabetes, chronic obstructive pulmonary disease (COPD) were reported in 38 (18.5%), 108(52.7%), 57(27.8%), 79(38.5%), 33(16.1%), 27(13.2%), 24(11.7%),27(13.2%),13(6.3%), 16 (7.8%), 14 (6.8%) patients respectively (Table 1).
Table 1
The Demographics and clinical characteristics of 205 patients.

|                          | Total (n=205) | Low-risk (n=95) | Intermediate-low risk (n=56) | Intermediate-high risk (n=30) | High risk (n=24) | P value |
|--------------------------|---------------|-----------------|-----------------------------|-------------------------------|------------------|---------|
| Gender(male%)            | 87 (42.4%)    | 43 (45.3%)      | 26 (46.4%)                  | 10 (33.3%)                    | 8 (33.3%)        | 0.474   |
| Age (years)              | 68 (23-92)    | 64 (23-91)      | 71 (40-90)                  | 67.5 (37-92)                  | 70.5 (47-88)     | 0.001   |
| DD                       | 1.32 (0.02-20.54) | 0.87 (0.02-8.38) | 1.80 (0.03-20.54)            | 2.62 (0.55-11.62)             | 2.83 (0.1-10.64) | 0.000   |
| TNF-α                    | 10.9 (4-322)  | 12.3 (4-322)    | 9.83 (4-115)                | 10.5 (5.2-38.5)               | 9.33 (4-57.8)    | 0.174   |
| IL-2R                    | 487 (122-2779) | 458 (181-2779)  | 517 (122-1946)              | 503 (266-963)                 | 518.5 (154-1346) | 0.046   |
| IL-6                     | 8.59 (2-212)  | 8.2 (2-208)     | 7.9 (2-212)                 | 8.86 (2-53.5)                 | 9.70 (2.26-49.9) | 0.962   |
| IL-8                     | 18.8 (5-1213) | 22.8 (6.8-1213) | 18.8 (5-980)                | 16 (5-180)                    | 14.9 (5.65-132)  | 0.046   |
| CRP                      | 8 (1-200)     | 8 (1-160)       | 8 (1-200)                   | 11 (1-168)                    | 7 (1-160)        | 0.357   |
| WBC                      | 6.8 (1.8-17.7) | 6.4 (3.1-17.7)  | 6.41 (1.8-14.2)             | 5.9 (3.8-11.1)                | 6.11 (1.8-13.5)  | 0.987   |
| ESR                      | 27 (2-120)    | 28 (2-120)      | 31.5 (2-120)                | 26 (2-97)                     | 24 (2-87)        | 0.530   |
| Pleural effusion         | 38 (18.5)     | 27 (28.4)       | 6 (10.7)                    | 4 (13.3)                      | 1 (4.2)          | 0.007   |
| Pulmonary infection      | 108 (52.7)    | 53 (55.8)       | 33 (58.9)                   | 11 (36.7)                     | 11 (45.8)        | 0.188   |
| Coronary heart disease   | 57 (27.8)     | 11 (11.6)       | 17 (30.4)                   | 19 (63.3)                     | 10 (41.7)        | 0.000   |
| Hypertension             | 79 (38.5)     | 32 (33.7)       | 24 (42.9)                   | 13 (43.3)                     | 10 (41.7)        | 0.620   |
| DVT                      | 33 (16.1)     | 11 (11.6)       | 9 (16.1)                    | 5 (16.7)                      | 8 (33.3)         | 0.081   |
| Cardiac arrhythmia       | 27 (13.2)     | 10 (10.5)       | 9 (16.1)                    | 6 (20)                        | 2 (8.3)          | 0.439   |
| Carcinoma                | 24 (11.7)     | 12 (12.6)       | 10 (17.9)                   | 1 (3.3)                       | 1 (4.2)          | 0.140   |

Note: D-dimer (DD); c-reaction protein (CRP); white blood cell (WBC); erythrocyte sedimentation rate (ESR); deep venous thrombosis (DVT); chronic obstructive pulmonary disease (COPD)
The comparison of clinical characteristics among different PE severity groups.

Medians of age (P=0.001), D-dimer (P=0.000), IL-2R (P=0.046) and IL-8 (P=0.046) were found statistically different among different PE severity groups. A raising tendency of D-dimer levels and a decreasing tendency of IL-8 levels were detected as PE severities increase. No significant differences were found in other biomarkers such as TNF-α, IL-6, CRP, WBC, and ESR among groups. With respect to commodities, rates of pleural effusion (P=0.007), coronary heart disease (P=0.000) and respiratory failure (P=0.003) were found statistically different among groups (Table 1).

Correlation between biomarkers and PE severity.

A spearman rank correlation analysis showed a negative correlation between IL-8 levels and PE severity (r= -0.466, P=0.018). A week negative correlation between TNF-α and PE severity was also found (r= -0.14, P=0.046). There was a positive correlation between Age and PE severities (r=0.280, P=0.000) and between D-dimer and PE severities (r=0.527, P=0.000) respectively. No significant correlation was found between other biomarkers (IL-2R, IL-6, CRP, WBC, ESR) and PE severity (Table 2).
Table 2
Correlation between PE severity and cytokine levels. (Spearman rank correlation analysis).

| PE severity | Variables | Correlation coefficient | P value |
|-------------|-----------|-------------------------|---------|
|             | Age       | 0.280                   | 0.000   |
|             | DD        | 0.527                   | 0.000   |
|             | TNF-α     | -0.14                   | 0.046   |
|             | IL-2R     | 0.072                   | 0.308   |
|             | IL-6      | 0.11                    | 0.118   |
|             | IL-8      | -0.466                  | 0.018   |
|             | CRP       | 0.019                   | 0.784   |
|             | WBC       | -0.042                  | 0.547   |
|             | ESR       | 0.064                   | 0.36    |

Note: D-dimer (DD); c-reaction protein (CRP); white blood cell (WBC); erythrocyte sedimentation rate (ESR);

Association between commodities and PE severity.

An ordinal multinomial Logistic regression revealed that with comorbidities of pleural effusion [0.433 (0.196-0.957) (P=0.039)], coronary heart disease [3.76 (1.99-7.10) (P=0.000)], deep venous thrombosis [2.40 (1.15-5.01) (P=0.019)] respiratory failure [2.92 (1.33-6.4) (P=0.007)] were correlated with the severity of PE. While no significant correlation was found between PE severity and commodities regarding pulmonary infection, hypertension, cardiac arrhythmia, carcinoma, renal dysfunction, diabetes, and COPD in current study (Table 3).
Table 3
The correlation between comorbidities and PE severity. (Ordinal multinomial Logistic regression analysis)

| Comorbidities (without=1) | Odds ratio | 95%CI       | P value |
|----------------------------|------------|-------------|---------|
| Pleural effusion           | 0.433      | 0.196-0.957 | 0.039   |
| Coronary heart disease     | 3.761      | 1.992-7.102 | 0.000   |
| DVT                        | 2.404      | 1.152-5.014 | 0.019   |
| Respiratory failure        | 2.921      | 1.333-6.402 | 0.007   |
| Pulmonary infection        | 1.152      | 0.631-2.101 | 0.645   |
| Hypertension               | 0.957      | 0.538-1.703 | 0.881   |
| Cardiac arrhythmia         | 1.279      | 0.579-2.823 | 0.543   |
| Carcinoma                  | 1.084      | 0.441-2.665 | 0.860   |
| Renal dysfunction          | 1.233      | 0.414-3.676 | 0.707   |
| Diabetes                   | 1.923      | 0.704-5.25  | 0.202   |
| COPD                       | 0.872      | 0.290-2.624 | 0.808   |

Note: deep venous thrombosis (DVT); chronic obstructive pulmonary disease (COPD)

Discussion

In the present study, we investigated the relationship between plasma cytokines as well as comorbidities and PE severity. To the best of our knowledge, this is the first study to investigate the association between cytokines and PE severity in the literature. According to our study, a negative correlation between IL-8 levels and PE severity was found. A weak negative correlation between TNF-α and PE severity was also found. We didn't observe any significant correlation between cytokines like IL-6, IL2R, CRP, WBC, ESR, and PE severity. In addition, we found that patients with comorbidities regarding coronary heart disease, deep venous thrombosis, and respiratory failure may have higher risk to suffer a more severe PE.

IL-8, the most important C-X-C chemokine, is produced by both inflammatory cells and structural cells including monocytes, neutrophils, endothelial cells, and epithelial cells. It was the most powerful chemoattractant of neutrophils [11]. As previous study, elevated IL-8 level was found in PE patients compared to control [12]. According to our study, once regarding to PE severity, elevated IL-8 may be a protect factor. This result was consistent with Henke's study. Used rats VTE model, Henke and colleagues found that extrinsic IL-8 treatment enhances thrombus resolution through neovascularization and neutrophil recruitment. Invaded neutrophils modulate collagen and fibrin degradation through the secretion of matrix metalloproteinases (MMP) in the thrombus. In addition, neovascularization is part of thrombus remodeling and involves the vascular endothelial growth factor (VEGF) that contributes to vein
recanalization [13]. Whether the decreased level of IL-8 contributes to the severity of pulmonary embolism by affecting thrombus absorption needs further research. Nosaka and colleagues found that TNFα may have a beneficial role during thrombus resolution by promoting fibrinolysis, collagenolysis and neovascularization [14]. In our study, the negative correlation between TNFα and PE severity is week. Whether a strong correlation could occur when increase the sample size is need to further research. Elevated IL-6 circulating levels were found in VTE patients compared to healthy controls which indicated an important role of IL-6 in VTE even the underlying mechanism is unclear [15, 16]. But in our study, there was no significant difference of IL-6 among groups and no significant correlation between IL-6 and PE severity.

Further, we investigated whether the presence of comorbidity at the time of diagnosis of PE could influence PE severity. As our data shown, PE patients with coronary heart disease, DVT, and respiratory failure had increased risk of 3.76-fold, 2.4-fold, 2.92-fold to suffer more sever PE respectively. As a previous study revealed, patients with coronary heart disease have a higher prevalence of PE than those without cardiovascular disease which indicated similar risk factors of coronary heart disease and PE [17]. In addition, patients with coronary heart disease usually have lower cardiac reserve function. When occurred with PE, hemodynamics instability and elevated biomarkers such as TNI and NT-proBNP may increase the PE severity. As another type of VTE, DVT usually coexist with PE. The diagnosis of concomitant DVT has been identified as an independently risk factor of death within the first 3 months after acute PE which indicated a more sever PE [18]. The underlying mechanism of respiratory failure caused by PE is the sever mismatch of ventilation and perfusion which results in a decreased diffusing capacity of the lungs. Furthermore, respiratory failure contributes to myocardial hypoxia injury and increase the expression of cardiac troponin which would increase the PE severity. Unfortunately, we didn't found association between comorbidities and cytokines levels (data not shown), which indicated that comorbidities do not affect PE severity through cytokine levels.

There are several limitations to our study that must be addressed. First, the small number of high-risk PE patients must be emphasized, bearing the risk of sample size error. Second, the retrospective design of the study limited the richness of the research. We didn’t observe the dynamic changes of cytokines in the course of disease. A prospective, ideally designed study with physicians randomly blinded to routinely collected data would be required to solve the above problems.

**Conclusion**

IL-8 is negative correlated with PE severity. Patients with comorbidities regarding coronary heart disease, deep venous thrombosis, and respiratory failure may have higher risk to suffer a more sever PE.

**Abbreviations**

CRP, C-reactive protein; CTPA, computed tomography pulmonary angiography; DVT, deep vein thrombosis; ESR, erythrocyte sedimentation rate; IL, interleukin; IFN-γ, Interferon γ; NT-pro-BNP, N-terminal pro-
natriuretic peptide; PE, pulmonary embolism; TGF-β, transforming growth factor-β; TPE, tuberculous pleural effusion; WBC, white blood cell.

Declarations

Ethics approval and consent to participate

This study complied with the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (NO. XHEC-D-2021-170).

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from Xiaoming Li (email: lixiaoming13734@126.com) on reasonable request.

Competing interests

The authors declared no competing interests.

Funding

No funding.

Authors’ contributions

XML conceived the study and participated in its design and performance, statistical analysis, and drafting and revising the manuscript. YKL conceived the study and participated in its design and performance, statistical analysis, and drafting and revising the manuscript. WJY and XC conceived the study and participated in its design and performance. XJG conceived the study, participated in its design and coordination, and revised the manuscript. WG conceived the study, participated in its design and coordination, and revised the manuscript. All authors reviewed the manuscript.

Acknowledgements

Not Applicable.

References
1. Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res 2016;118:1340–1347.

2. Keller K, Hobohm L, Ebner M, Kresoja KP, Munzel T, Konstantinides SV, Lankeit M. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. Eur Heart J 2020;41:522–529.

3. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ní Áinle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603.

4. Branchford BR, Carpenter SL. The Role of Inflammation in Venous Thromboembolism. Front Pediatr. 2018;6:142.

5. Santana DC, Emara AK, Orr MN, Klika AK, Higuera CA, Krebs VE, Molloy RM, Piuzzi NS. An Update on Venous Thromboembolism Rates and Prophylaxis in Hip and Knee Arthroplasty in 2020. Medicina (Kaunas). 2020;56(9):416.

6. Najem MY, Couturaud F, Lemarié CA. Cytokine and chemokine regulation of venous thromboembolism. J Thromb Haemost. 2020;18(5):1009–1019.

7. Reitter EM, Ay C, Kaider A, Pirker R, Zielinski C, Zlabinger G, Pabinger I. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients. Clin Exp Immunol. 2014;177(1):253–60.

8. Melo AKG, Milby KM, Caparroz ALMA, Pinto ACPN, Santos RRP, Rocha AP, Ferreira GA, Souza VA, Valadares LDA, Vieira RMRA, Pileggi GS, Trevisani VFM. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis. PLoS One. 2021;16(6):e0253894.

9. Li X, Qin Y, Ye W, Chen X, Sun D, Guo X, Gu W. Diagnostic performance of D-dimer in predicting pulmonary embolism in tuberculous pleural effusion patients. BMC Pulm Med. 2021;21(1):177.

10. Konstantinides S. 2019 ESC guidelines on pulmonary embolism: Novelties and unanswered questions. Eur J Intern Med. 2020;74:1–4.

11. Fonollosa A, Garcia-Arumi J, Santos E, Macia C, Fernandez P, Segura RM, Zapata MA, Rodriguez-Infante R, Boixadera A, Martinez-Castillo V. Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion. Eye (Lond). 2010;24(7):1284–90.

12. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol. 2002;116(1):173–7.

13. Henke PK, Wakefield TW, Kadell AM, Linn MJ, Varma MR, Sarkar M, Hawley A, Fowlkes JB, Strieter RM. Interleukin-8 Administration Enhances Venous Thrombosis Resolution in a Rat Model. Journal of Surgical Research 2001; 99: 84–91.
14. Nosaka M, Ishida Y, Kimura A, Kuninaka Y, Taruya A, Furuta M, Mukaida N, Kondo T. Contribution of the TNF-α (Tumor Necrosis Factor-α)–TNF-Rp55 (Tumor Necrosis Factor Receptor p55) Axis in the Resolution of Venous Thrombus. Arterioscler Thromb Vasc Biol 2018; 38: 2638–50.

15. Roumen-Klappe EM, den Heijer M, van Uum SHM, van der Ven-Jongekrijg J, van der Graaf F, Wollersheim H. Inflammatory response in the acute phase of deep vein thrombosis. Journal of Vascular Surgery 2002; 35: 701–6.

16. Zhang Y, Zhang Z, Wei R, Miao X, Sun S, Liang G, Chu C, Zhao L, Zhu X, Guo Q, Wang B, Li X. IL (Interleukin)-6 Contributes to Deep Vein Thrombosis and Is Negatively Regulated by miR-338-5p. Arterioscler Thromb Vasc Biol. 2020; 40(2):323–334.

17. Zuin M, Rigatelli G, Faggian G, Zonzin P, Roncon L. Short-term outcome of patients with history of significant coronary artery disease following acute pulmonary embolism. Eur J Intern Med 2016;34:e16–e17.

18. Jiménez D, Aujesky D, Díaz G, Monreal M, Otero R, Martí D, Marin E, Aracil E, Sueiro A, Yusen RD; RIETE Investigators. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2010;181:983991.